1,869 results on '"Freeman, Gordon J."'
Search Results
102. Supp. Movie 1 from Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
103. Table S3 from Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
104. Supplementary Table 2 from Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade
105. Supplementay Figures S1-3 from Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer
106. Data from Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL
107. Data from Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade
108. Supplementary Figure Legends from BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non–Small Cell Lung Cancer
109. Table S1-S3; Figure S1-S13 from BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non–Small Cell Lung Cancer
110. Supplementary Data from Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
111. Supplementary Table 7 from Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade
112. Supplementary Table 1 from Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
113. Data from Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma
114. Data from Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer
115. Data from Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade
116. Table S1 from Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade
117. Supplementary Methods from Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma
118. Supplementary Table 1 from Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade
119. Supplementary Figures from Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade
120. Supplemental Table I from PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells
121. Supplemental Table 1 from Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma
122. Supplementary Figures 1 through 7 and Supplementary Table 1 from Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model
123. Data from PD-L1 Binds to B7-1 Only In Cis on the Same Cell Surface
124. Data from Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes
125. Supplemental Figure and Table Legends from PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells
126. Supplementary Table 3 from Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade
127. Supplementary Table 4 from Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade
128. Supplementary Table 6 from Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade
129. Supplementary Figures from Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
130. Supplementary Figures 1-3 from Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL
131. Supplementary Methods from MicroRNA MIR21 and T Cells in Colorectal Cancer
132. Supplementary Methods from Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
133. Supplementary Methods from Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model
134. Supplementary Figures S1-S4 and Table S1 from PD-L1 Binds to B7-1 Only In Cis on the Same Cell Surface
135. Supplementary Figure Legend from Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma
136. Supplementary Figure Legends from Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model
137. Supplementary Figure S2 from Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma
138. Supplementary Figures and Legends from Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade
139. Supplemental Table 2 from Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma
140. Supplementary Figure Legends from Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
141. Data from Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade
142. Supplemental Figures and Tables from Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
143. Supplementary Figure Legend from Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade
144. Supplementary Tables 1 through 8 from Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition
145. Supplementary Figures from Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade
146. Supp. Movie 2 from Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
147. Supplementary Figure from Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma
148. Data from PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer
149. Supplementary Table 2 from PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
150. Table S1 from Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.